No headlines found.
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
PRNewswire (Wed, 22-Apr 5:40 AM ET)
Globe Newswire (Mon, 20-Apr 4:05 PM ET)
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Kailera Therapeutics trades on the NASDAQ stock market under the symbol KLRA.
As of May 1, 2026, KLRA stock price climbed to $25.15 with 525,596 million shares trading.
KLRA has a market cap of $3.26 billion. This is considered a Mid Cap stock.
KLRA support price is $23.27 and resistance is $26.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KLRA shares will trade within this expected range on the day.
